AEON Biopharma Files S-1/A for Share Registration

TL;DR

AEON Biopharma registering 6.97M shares, cash up to $138.8M. Big move for biotech investors.

AI Summary

AEON Biopharma, Inc. filed an S-1/A on May 31, 2024, to register 6,971,500 shares of common stock. The company, formerly Priveterra Acquisition Corp., is focused on developing treatments for diseases, with a primary candidate, ABP-101, for glioblastoma. The filing indicates a significant increase in cash and cash equivalents from $37.16 million to $138.85 million.

Why It Matters

This filing is crucial for investors as it details the registration of a substantial number of shares, potentially impacting the stock's liquidity and valuation. It also provides updated financial figures for AEON Biopharma.

Risk Assessment

Risk Level: medium — The company is in the pharmaceutical development stage, which inherently carries high risks related to clinical trials, regulatory approval, and market adoption.

Key Numbers

• 6,971,500 — Shares Registered (This represents the total number of shares AEON Biopharma is registering for potential sale or issuance.)
• $138.85M — Cash and Cash Equivalents (Indicates a significant increase in the company's liquidity, important for funding operations and development.)
• $37.16M — Previous Cash Balance (Shows the substantial growth in the company's cash position.)

Key Players & Entities

• AEON Biopharma, Inc. (company) — Filer of the S-1/A
• Priveterra Acquisition Corp. (company) — Former name of AEON Biopharma, Inc.
• 6,971,500 (dollar_amount) — Number of shares to be registered
• May 31, 2024 (date) — Filing date of the S-1/A
• $138.85 million (dollar_amount) — Cash and cash equivalents as of the filing date
• $37.16 million (dollar_amount) — Cash and cash equivalents previously reported

FAQ

Key Financial Figures

• $0.0001 — ares of Class A common stock, par value $0.0001 per share (the "Common Stock") issued i
• $10.00 — s") at an equity consideration value of $10.00 per share, (ii) the resale of 1,075,000
• $7.00 — where in this prospectus) at a price of $7.00 per share, (iii) the resale of 6,275,00
• $10.63 — where in this prospectus) at a price of $10.63 per share, (iv) the resale of up to 28,
• $1.00 — where in this prospectus) at a price of $1.00 per share (assuming the maximum accrued
• $1.50 — vate Placement Warrants") at a price of $1.50 per warrant, by the holders thereof.
• $0.10 — lic Warrants, for a redemption price of $0.10 per Public Warrant, that remained outst
• $45.9 million — ive up to an aggregate of approximately $45.9 million from the cash exercise of the Private P
• $11.50 — ch of our Private Placement Warrants is $11.50 per warrant and the last reported sales
• $1.44 — of our Common Stock on May 30, 2024 was $1.44. The likelihood that holders of Private
• $0.004 — rospectus) purchased by the Sponsor for $0.004 per share prior to Priveterra's initial
• $3.0 billion — evelop ABP-450 to address the estimated $3.0 billion global therapeutic botulinum toxin mark
• $4.4 billion — n market, which is projected to grow to $4.4 billion in 2027, according to the Decision Reso

Filing Documents

• aeon-20240331xs1a.htm (S-1/A) — 6338KB
• aeon-20240331xex5d1.htm (EX-5.1) — 38KB
• aeon-20240331xex23d1.htm (EX-23.1) — 2KB
• aeon-20240331xex23d2.htm (EX-23.2) — 3KB
• aeon-20240331xexfees.htm (EX-FILING FEES) — 171KB
• aeon-20240331xs1a009.jpg (GRAPHIC) — 12KB
• aeon-20240331xs1a012.jpg (GRAPHIC) — 63KB
• aeon-20240331xex5d1001.jpg (GRAPHIC) — 6KB
• aeon-20240331xex5d1002.jpg (GRAPHIC) — 2KB
• aeon-20240331xex23d2001.jpg (GRAPHIC) — 5KB
• 0001104659-24-067125.txt ( ) — 24892KB
• aeon-20240331.xsd (EX-101.SCH) — 140KB
• aeon-20240331_def.xml (EX-101.DEF) — 802KB
• aeon-20240331_lab.xml (EX-101.LAB) — 793KB
• aeon-20240331_cal.xml (EX-101.CAL) — 71KB
• aeon-20240331_pre.xml (EX-101.PRE) — 1227KB
• aeon-20240331xs1a_htm.xml (XML) — 3588KB

USE OF PROCEEDS

USE OF PROCEEDS 56 DIVIDEND POLICY 57

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 58

BUSINESS

BUSINESS 79 MANAGEMENT 108 EXECUTIVE AND DIRECTOR COMPENSATION 114 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 130 PRINCIPAL STOCKHOLDERS 139 REGISTERED HOLDERS 141 DESCRIPTION OF OUR SECURITIES 151 PLAN OF DISTRIBUTION 162 LEGAL MATTERS 165 EXPERTS 166 WHERE YOU CAN FIND MORE INFORMATION 167 INDEX TO FINANCIAL STATEMENTS F-1 i Table of Contents ABOUT THIS PROSPECTUS This prospectus is part of a registration statement that we filed with the United States Securities and Exchange Commission, or the SEC, using a "shelf" registration process. We will not receive any proceeds from the sale by the Registered Holders of the securities offered by them described in this prospectus. This prospectus also relates to the issuance by us of the shares of Common Stock issuable upon the exercise of the Warrants. We will not receive any proceeds from the sale of shares of Common Stock underlying the Warrants pursuant to this prospectus, except with respect to amounts received by us upon the exercise of the Warrants for cash. We may also file a prospectus supplement or post-effective amendment to the registration statement of which this prospectus forms a part that may contain material information relating to these offerings. The prospectus supplement or post-effective amendment may also add, update or change information contained in this prospectus with respect to that offering. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement or post-effective amendment, you should rely on the prospectus supplement or post-effective amendment, as applicable. Before purchasing any securities, you should carefully read this prospectus, any post-effective amendment, and any applicable prospectus supplement, together with the additional information described under the heading " Where You Can Find More Information ." Neither we nor the Registered Holders have authorized anyone to provide y

View Full Filing

View this S-1/A filing on SEC EDGAR